Oncolytics Biotech Inc. provided details from abstracts presented at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, showcasing new efficacy and safety data for pelareorep. In GOBLET Cohort 4, evaluating pelareorep with atezolizumab in relapsed anal carcinoma, four of twelve evaluable patients achieved a partial response, resulting in an objective response rate (ORR) of 33%. This ORR is notable as historical response rates to checkpoint inhibitor monotherapy are typically between 10-24%.
The anal cancer data also included one patient with a prolonged complete response that persisted for over 15 months, indicating durable clinical benefit. Stage 2 enrollment for this cohort, involving 18 additional evaluable patients, has commenced. The company anticipates that additional data from Stage 2 will provide a sufficiently strong efficacy signal to advance this treatment regimen into a registration-enabling study.
For pancreatic cancer, the safety run-in for GOBLET Cohort 5, which combines pelareorep with modified FOLFIRINOX with or without atezolizumab, has completed enrollment. The Data Safety Monitoring Board (DSMB) and the Paul Ehrlich Institute (PEI) reviewed the safety data and recommended that patient enrollment continue without modification, confirming a manageable safety profile for this new chemotherapy regimen.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.